CooperVision Introduces SightGlass Vision™ Spectacle Lenses in the Netherlands to Help Slow the Progression of Myopia in Children

Launch Marks Europe’s First Commercial Availability of the Evidence-Based Technology

EERBEEK, 5 October 2021 - CooperVision today announced the Dutch launch of SightGlass Vision™ spectacle lenses with Diffusion Optics Technology^™§, which are specifically designed for and have been shown to slow the progression of myopia in children.¹ Eye care professionals (ECPs) in the Netherlands are the first in the world to have broad access to this innovation, which are ideal for children as young as age six and for children who may not yet be ready for contact lens wear.

“Myopia has been traditionally addressed with spectacles or contact lenses which correct vision, but do not slow down the speed at which myopia progresses. Clinically useful interventions entering the market offer eye care professionals the ability to embrace evidence-based myopia management as standard of care,” said Alex Lamse, Managing Director EMEA, CooperVision Specialty EyeCare. “Expanding our portfolio with SightGlass Vision™ spectacle lenses gives ECPs another accessible optical intervention that has been shown to correct children’s vision and slow myopia progression today while growing their practices.”^1,2

CooperVision’s groundbreaking MiSight^® 1 day myopia control soft contact lenses are available in the Netherlands as well, specifically designed for children from eight years old and upwards.³ With the addition of SightGlass Vision™ spectacle lenses, ECPs can address myopia in pediatric patients across a wide age range. The company also offers a range of ortho-k contact lens brands for myopia management, including Procornea DreamLite^® Night Lenses which have received a CE Mark for myopia control.

Myopia progression in children continues to grow in prevalence and severity, elevating it to one of the most important issues facing ECPs and parents today. Globally, myopia is projected to affect five billion people by 2050, more than doubling today’s numbers.⁴ There is also a increase of myopia with children in the Netherlands. Myopic progression has been linked to sight-threatening conditions later in life such as cataracts, retinal detachment, glaucoma and myopic maculopathy.⁵

CooperVision’s Global Myopia Attitudes and Awareness Study indicates that 82% of ECPs worry their young patients will have significant eye health issues associated with myopia as they grow older, yet more than half say parents do not understand these future eye health risks. Once these risks were explained, 87% of parents were open to learning more about myopia management solutions. ECPs also identified that the most important reasons for specific myopia management options included clinical results performance, ease of use for children, and regulatory approvals.⁶

SightGlass Vision™ Spectacle Lenses

CooperVision’s commitment to evidence-based approaches is central to its introduction of SightGlass Vision™ spectacle lenses. CooperVision acquired SightGlass Vision, which developed Diffusion Optics Technology^™, earlier this year.

The company’s CYPRESS clinical study⁷ enrolled, randomized, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada. At the time of enrollment, subjects were six to 10 years old having myopia between -0.75D and -4.50D.

When children wore SightGlass Vision™ spectacle lenses full time, they were shown to reduce the rate of myopia progression by 47% on average over the first two years of the multi-year study as measured by cycloplegic autorefraction,⁸ compared to single vision spectacle lenses. Axial length growth was slowed by 24% on average over 24 months.⁹ Moreover, after two years of wearing SightGlass Vision™ spectacle lenses in the CYPRESS clinical study, 85% of children showed less than one diopter of myopia progression.¹⁰

Distance visual acuity with SightGlass Vision™ lenses was on average better than 6/6 (20/20) at each visit and similar to single vision spectacle lenses.¹¹ In the study, children on average wore both SightGlass Vision™ lenses and standard single vision spectacle lenses more than 12 hours each day over a 24-month period, suggesting that children readily adapted to the Diffusion Optics Technology^™.¹²

SightGlass Vision™ spectacle lenses hold a CE Mark declaration for myopia control.

“For more than a decade, CooperVision has been at the forefront of addressing myopia progression through research, clinical education and innovative product development. We are enthusiastic about bringing SightGlass Vision™ spectacle lenses to eye care professionals across the Netherlands, partnering with them to change the course of children’s vision and offer them an even more promising future,” said Alex Lamse.

^§ Indications for use: Diffusion Optics Technology (DOT) spectacle lenses are indicated for the correction of refractive ametropia (myopia and/or astigmatism) and for the reduction in the rate of myopic progression in phakic children who are aged 6 to 12 years old with non-diseased eyes. DOT spectacle lenses should be worn constantly for all activities except for those outlined in WARNINGS (a minimum of 10 hours per day). These lenses are manufactured by SightGlass Vision in Palo Alto, CA, USA.

About CooperVision Specialty EyeCare
CooperVision Specialty EyeCare (SEC) specialises in producing customised lenses with the highest precision and quality. The SEC division is part of the CooperVision organisation, one of the world's largest contact lens manufacturers with more than 10,000 employees. Our products are sold in more than 100 countries, from China to Europe and from Africa to North and South America.

The SEC division focuses on innovative customised contact lenses to achieve maximum vision for every person worldwide, regardless of the condition of the eye. By investing in our people and technology every day, we are building our strength and future. The EMEA SEC Division is headquartered in Eerbeek, the Netherlands. There, more than 120 employees are working towards a common goal, which is to let everyone experience their world to the fullest. For more information, please visit www.coopervisionsec.nl.

About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 12,000 with products sold in over 100 countries. For more information, please visit www.coopercos.com. 

Media contact
Janine van Milligen en Sifra Hissink
[email protected]
+31(0)313 677 677

_{^{1 Reduction in progression of spherical equivalent refraction and axial length from baseline over 24 months was 47% and 24% on average, respectively (p≤0.0041). 2 Pupil center height measurements required. 3 Holden et al, - Global Prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology 2016. 123(5):1036-1042. 4 Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363. 5 CooperVision Specialty EyeCare data on file 2019. Global survey by Decision Analyst with 402 ECPs ND 1,009 parents in UK, Canada, Germany, Spain, Hong Kong, Australia/NZ. 6 Compared to control spectacle lenses as measured by spherical equivalent refraction (SER) cycloplegic autorefraction. 7 Mean change in axial length of 0.15 mm with SightGlass Vision™ spectacle lenses compared to 0.30 mm with single vision spectacle lenses. 8 Versus 65% of control subjects, p=0.0032 (n=74 test, n=87 control). 9 Mean high-contrast distance (LogMAR) VA was -0.04, -0.06, -0.06, -0.08 at the baseline, 30-day, 6-month and 12-month visits respectively. 10 SightGlass Vision™ spectacle lenses are indicated to be worn constantly for all activities (a minimum of 10 hours per day) except for those outlined in WARNINGS section within the DOT 0.2 Trivex Spectacle Lenses indications for use document. 11 Mean high-contrast distance (LogMAR) VA was -0.04, -0.06, -0.06, -0.08 at the baseline, 30-day, 6-month and 12-month visits respectively. 12 SightGlass Vision™ spectacle lenses are indicated to be worn constantly for all activities (a minimum of 10 hours per day) except for those outlined in WARNINGS section within the DOT 0.2 Trivex Spectacle Lenses indications for use document.}}